Financing funds development of respiratory therapy
Gilde Healthcare Partners has announced an investment in Prosonix, a developer of respiratory therapies based on its proprietary particle-engineering technology.
Alongside Gilde Healthcare Partners, new investor Ventech participated in an £11.4m financing round. Current backers Entrepreneurs Fund, Quest for Growth and Solon Ventures also participated.
The proceeds of the financing will be used to progress the Prosonix’s emerging proprietary product pipeline of mono- and multi-component combination therapies, and to fund Phase 2 Clinical trials as required.
Oxford-based Prosonix’s patented particle-engineering technology is said to provide an opportunity to develop novel and generic mono and combination respiratory medicines in a range of metered dose and dry-powder inhalers.
As part of the financing, Edwin de Graaf from Gilde Healthcare Partners and Karl Nägler from Ventech will join the Prosonix board of directors.
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
Experts speculate over cause of Iberian power outages
The EU and UK will be moving towards using Grid Forming inverters with Energy Storage that has an inherent ability to act as a source of Infinite...